7-Diethylamino-3(2`-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells.
- Authors
- Kim, Su-Nam; Kim, Nam Hyun; Park, Yeon Sook; Kim, Hanna; Lee, Seokjoon; Wang, Qian; Kim, Yong Kee
- Issue Date
- Jun-2009
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Citation
- BIOCHEMICAL PHARMACOLOGY, v.77, no.12, pp 1773 - 1779
- Pages
- 7
- Journal Title
- BIOCHEMICAL PHARMACOLOGY
- Volume
- 77
- Number
- 12
- Start Page
- 1773
- End Page
- 1779
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/148057
- DOI
- 10.1016/j.bcp.2009.03.007
- ISSN
- 0006-2952
1873-2968
- Abstract
- Microtubules are a proven target for anticancer drug development because they are critical for mitotic spindle formation and the separation of chromosomes at mitosis. We here report a novel synthetic microtubule inhibitor 7-diethylamino-3(2′-benzoxazolyl)-coumarin (DBC). DBC causes destabilization of microtubules, leading to a cell cycle arrest at G2/M stage. In addition, human cancer cells are more sensitive to DBC (IC50 44.8–475.2 nM) than human normal fibroblast (IC50 7.9 μM), and DBC induces apoptotic cell death of cancer cells. Furthermore, our data show that DBC is a poor substrate of drug efflux pumps and effective against multidrug resistant (MDR) cancer cells. Taken together, these results describe a novel pharmacological property of DBC as a microtubule inhibitor, which may make it an attractive new agent for treatment of MDR cancer.
- Files in This Item
-
Go to Link
- Appears in
Collections - 약학대학 > 약학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.